Compare Duke Energy Corp (DUK) vs Novavax Inc (NVAX) Price & Performance

Duke Energy (DUK) trades at $122.97, up 1.46% today, with a bearish technical signal but strong fundamentals. Recent earnings beat estimates for three consecutive quarters, with Q2 2026 EPS at $1.43 versus $1.30 expected. The company maintains solid profitability, with a net income margin of 15.78% and ROE of 10.01%. Cash flow trends show consistent operational strength, though investing outflows remain high due to infrastructure spending.

The outlook is mixed: analyst consensus is a Buy with a $136.17 price target, but technical indicators signal near-term caution. Key risks include regulatory scrutiny and high debt levels, while opportunities lie in data-center demand growth and dividend stability. Investors should weigh strong fundamentals against bearish technicals and macroeconomic headwinds.

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.